PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis

Abstract

Background

To illustrate the accurate location of Poly-ADP-ribose polymerase inhibitor (PARPi) as the first-line maintenance therapy in advanced ovarian cancer (AOC).

Methods

Search for eligible studies and calculate clinical outcomes.

Results

PARPi as a first-line maintenance treatment significantly prolonged the BRCAmut population and the homologous recombination deficiency (HRD) positive population.

Conclusion

PARPi as first-line maintenance therapy significantly improves the progression-free survival in AOC, especially in the BRCAmut and HRD positive populations. PARPi has been becoming the standard first-line maintenance therapy for AOC.

Keywords:

• PARP inhibitor
• ovarian cancer
• maintenance therapy
• first-line
• meta-analysis

Acknowledgments

The authors thank Xiaoqian Chen for her guidance on polishing this article.

Consent to publish

All authors agreed to be accountable for the content of this paper.

Author contributions

QL contributed to the design of the study and was responsible for the integrity of the data and accuracy of the data analysis. QD and MH collected and extracted the clinical data. QD and MW were responsible for the statistical analysis and preparation of the figures and tables. QD and CW wrote the manuscript. All authors contributed to the review and approved the paper.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Additional information

Funding

This work was supported by National Natural Science Foundation of China [Grant No. 81301912], Beijing Municipal Health System High-level Health Person Foundation Project [Grant No. 2014-3-005], and Beijing Municipal Science & Technology Commission [Capital Features, Z161100000516083].